Veritas In Silico Inc. (JP:130A) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Veritas In Silico Inc. has formed a strategic partnership with Liverpool ChiroChem to accelerate mRNA-targeted drug discovery, leveraging complementary chemistry and biology platforms. The collaboration, which has already shown positive preliminary results, aims to develop first-in-class and best-in-class small molecule drugs. Both companies highlight the strong scientific and cultural fit that contributes to the effectiveness of their joint efforts.
For further insights into JP:130A stock, check out TipRanks’ Stock Analysis page.